Chelsea Therapeutics Inc.
But Chelsea Therapeutics Inc. (Nasdaq) lost about two-thirds of its market value after the company's experimental drug to treat a neurological disorder missed the main goal of a late-stage study, confirming some apprehension that the trial design could skew results from the control arm. The company said the drug did not demonstrate a statistically significant improvement, measured by the mean score of dizziness or light-headedness of Orthostatic Hypotension Symptom Assessment, compared to a dummy drug. Chelsea is developing the drug, Droxidopa, as a treatment for symptomatic neurogenic orthostatic hypotension (NOH)--a neurological disorder that causes blood pressure to drop when the afflicted person assumes a standing position. Company shares closed the week down $4.17 to $2.73.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Medical Stock Spotlight|
|Article Type:||Brief article|
|Date:||Sep 28, 2009|
|Previous Article:||Nektar Therapeutics Inc.|
|Next Article:||Study finds even more may benefit from Statins.|